New pill for ulcerative colitis passes first safety check in healthy volunteers
NCT ID NCT06363383
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested whether an oral biologic drug called MB-001 is safe in 48 healthy adults. Participants received either a single dose or five daily doses of the drug or a placebo. The main goal was to check for side effects and see how the body processes the drug. This is a first step toward possibly treating ulcerative colitis.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MB-001 (an oral biologic drug)
What this could lead to
If safe, this could lead to larger trials testing whether MB-001 helps control ulcerative colitis symptoms.
What could go wrong
This is a very early Phase 1 safety study in healthy people, not patients. It is too soon to know if MB-001 will work for ulcerative colitis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CMAX
Adelaide, South Australia, 5000, Australia